The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead Vt Regulatory News (BVT)

Share Price Information for Baronsmead Vt (BVT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.50
Bid: 51.00
Ask: 54.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.882%)
Open: 52.50
High: 52.50
Low: 52.50
Prev. Close: 52.50
BVT Live PriceLast checked at -
Baronsmead Venture Trust is an Investment Trust

To achieve long-term investment returns for private investors by investing primarily in a diverse portfolio of UK growth businesses, whether unquoted or traded on AIM.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-yearly Report

13 Jun 2023 07:00

RNS Number : 4622C
Baronsmead Venture Trust PLC
13 June 2023
 

Baronsmead Venture Trust plc

Half-yearly report for the six months ended 31 March 2023

The Directors of Baronsmead Venture Trust plc are pleased to announce the unaudited half-yearly financial report for the six months to 31 March 2023. Copies of the half-yearly report can be obtained from the following website: www.baronsmeadvcts.co.uk.

Our investment objective

· Baronsmead Venture Trust plc (the "Company") is a tax efficient listed company which aims to achieve long-term investment returns for private investors, including tax-free dividends.

 

Investment policy

· To invest primarily in a diverse portfolio of UK growth businesses, whether unquoted or traded on the Alternative Investment Market ("AIM").

· Investments are made selectively across a range of sectors in companies that have the potential to grow and enhance their value.

 

Dividend policy

· The Board will, wherever possible, seek to pay two dividends to shareholders in each financial year, typically an interim dividend in September and a final dividend following the Annual General Meeting.

· The Board will use, as a guide, when setting the dividends for a financial year, a sum representing 7 per cent. of the opening NAV of that financial year.

 

Key elements of the business model

Access to an attractive, diverse portfolio

The Company gives shareholders access to a diverse portfolio of growth businesses.

The Company will make investments in growth businesses, whether unquoted or traded on AIM, which are substantially based in the UK in accordance with the prevailing VCT legislation. Investments are made selectively across a range of sectors.

 

The Manager's approach to investing

The Manager endeavours to select the best opportunities and applies a distinctive selection criteria based on:

· Primarily investing in parts of the economy which are experiencing long term structural growth.

· Businesses that demonstrate, or have the potential for, market leadership in their niche.

· Management teams that can develop and deliver profitable and sustainable growth.

· Companies with the potential to become an attractive asset appealing to a range of buyers at the appropriate time to sell

In order to ensure a strong pipeline of opportunities, the Manager invests in building deep sector knowledge, networks and undertakes significant active marketing to target companies in preferred sectors. This approach generates a network of potentially suitable businesses with which the Manager maintains a relationship ahead of possible investment opportunities.

 

 

 

The Manager as an influential shareholder

The Manager is an engaged and supportive shareholder (on behalf of the Company) in both unquoted and significant quoted investments.

 

For unquoted investments, representatives of the Manager often join the investee board. The role of the Manager with investees is to ensure that strategy is clear, the business plan can be implemented and the management resources are in place to deliver profitable growth. The aim is to build on the business model and grow the company into an attractive target which can be sold or potentially floated in the medium term.

Financial highlights

400.9p Net asset Value ("NAV") total return to shareholders for every 100.0p invested at launch (April 1998).

NAV per share decreased 0.9 per cent. to 58.0p before deduction of dividends in the six months to 31 March 2023.

£25.0mn raised in the period (before costs).

£4.3mn Investments made into two new and three follow-on opportunities during the period (Unquoted: £3.2mn, Quoted : £1.1mn).

Cash returned to shareholders by date of investment

 

The table below shows the cash returned to shareholders that invested in Baronsmead Venture Trust plc dependent on their subscription cost, including the income tax available to be reclaimed on the subscription.

 

Year subscribed

Cash invested

 (p)

Income tax reclaim

(p)

 

Net cash invested

(p)

Cumulative dividends

paid#

 (p)

Return on cash invested# (%)

1998 (April)

100.00

20.00

80.00

181.40

201.4

1999 (May)

102.00

20.40

81.60

177.90

194.4

2000 (February)

137.00

27.40

109.60

174.70

147.5

2000 (March)

130.00

26.00

104.00

174.70

154.4

2004 (October) - C shares*

100.00

40.00

60.00

130.00

170.0

2009 (April)

91.60

27.48

64.12

113.50

153.9

2012 (December)

111.80

33.54

78.26

88.00

108.7

2014 (March)

103.80

31.14

72.66

70.50

97.9

2016 (February)

102.80

30.84

71.96

56.00

84.5

2017 (October)

94.76

28.43

66.33

38.00

70.1

2019 (February)

84.20

25.26

58.94

31.50

67.4

2019 (November)

76.80

23.04

53.76

24.00

61.3

2020 (January)

82.40

24.72

57.68

24.00

59.1

2020 (February)

80.10

24.03

56.07

20.50

55.6

2020 (March)

63.80

19.14

44.66

20.50

62.1

2020 (November)

75.20

22.56

52.64

17.50

53.3

2020 (December)

78.00

23.40

54.60

17.50

52.4

2021 (January)

81.30

24.39

56.91

17.50

51.5

2021 (February)

78.80

23.64

55.16

14.00

47.8

2021 (March)

80.90

24.27

56.63

14.00

47.3

2021 (December)

83.10

24.93

58.17

11.00

43.2

2022 (January)

82.40

24.72

57.68

11.00

43.3

2022 (March)

72.60

21.78

50.82

7.50

40.3

2023 (January)

64.25

19.28

44.97

4.50

37.0

2023 (March)

62.65

18.80

43.85

1.75

32.8

 

* C Share dividend calculated using conversion ratio of 0.9657, which is the rate the c shares were converted into ordinary shares.

* Includes proposed Interim dividend of 1.75p.

 * Shares were allotted pursuant to the 2023 Offer at individual prices for each investor in accordance with the allotment formula as set out in each Offer's Securities Note.

1. Average effective offer price based on allotment prices between 63.4p and 67.2p.2. Average effective offer price based on allotment prices between 61.5p and 64.5p.

Chair's statement

Fiona Miller Smith

Chair

Over what has been a turbulent six months, the Company's net asset value (NAV) declined slightly by 0.5p per share to 58.0p. Continued weakness in the value of the Company's unquoted investments was largely although not completely offset by the modestly positive performance of the listed portfolio. This is described more fully below, and highlights the benefits of the Company's investment policy of having a combination of unquoted and listed assets with the aim of providing a more consistent total return to shareholders over the medium to long term. After the period end, NAV recovered through further good performance of the listed portfolio, as reported on below.

Over the six months to 31 March 2023, inflation in the UK remained high and interest rates rose steadily. Consequently, UK economic conditions continued to be challenging and this has generated much uncertainty across the financial markets. This was compounded in the first quarter of 2023 by the collapses of Silicon Valley Bank and Credit Suisse in close succession which led to fears of a more widespread banking sector contagion.

At the time of writing, it's fair to say that consumer and business confidence remain fragile. In such an environment we might expect there to be further weakness in the valuation of smaller companies and this is particularly the case with the types of business the VCT rules require the Company to invest in. However, the Manager continues to believe that, in aggregate, the

fundamentals of the underlying portfolio companies remain robust and the growth prospects for the majority of investee companies continue to be positive over the medium term.

Results

During the six months to 31 March 2023, the Company's NAV per share decreased 0.9 per cent. from 58.5p to 58.0p after the payment of a final dividend of 2.75p per share on 3 March 2023. The table below breaks down the movement in NAV over the six months.

 

 

Pence per ordinary share

NAV as at 1 October 2022 (after deducting the final dividend of 2.75p)

58.5

Valuation decrease (0.9 per cent.)

(0.5)

NAV as at 31 March 2023

58.0

 

 

The Board is pleased to report that over the two months to 31 May 2023, NAV was 59.1p per share, a 1.9 per cent. increase over the NAV as at 31 March 2023. This was driven by firmer quoted markets and further increases in the value of the Company's listed investments.

Dividends

The Board is pleased to declare an interim dividend of 1.75p per share to be paid on 8 September 2023 to shareholders on the register as of 11 August 2023. The Board is aware that dividends are an important part of the total return to the shareholders' investment in the Company. As such, the Board is aiming to achieve its dividend policy objective of an annual yield of 7.0 per cent. based on the NAV at the beginning of the financial year. Having said that, I must of course remind shareholders this is not a guarantee and that payment dates and the amount of future dividends depend on the level and timing of profitable realisations.

 

Portfolio review

The table below provides a summary of each asset class and the return generated during the period under review.

Asset class

NAV*

(£mn)

% of NAV*

Number of investees companies**

% return in the period***

Unquoted

44

22

41

(14)

AIM- traded companies

59

29

48

2

LF Gresham House UK Micro Cap Fund

29

14

48

7

LF Gresham House UK Multi Cap Income Fund

12

6

40

7

LF Gresham House UK Smaller Companies Fund

25

12

38

5

Liquid assets#

34

17

N/A

2

Total

203

100

215

(1)

 

*By value at 31 March 2023. **Includes investee companies with holdings by more than one fund. Total number of individual companies held is 166. ***Return includes interest received on unquoted realisations during the period. # Represents cash, OEICs and net current assets. % return in the period relates only to the OEICs.

The value of the unquoted portfolio decreased 13.6 per cent. in the six months to 31 March 2023. The drop in value was driven by a combination of lower benchmark market comparables and softening trading performance of the investee companies as a result of the decline in consumer confidence.

 

The value of the Company's portfolio of investments directly held in AIM-traded companies increased 2.1 per cent. in the six months to 31 March 2023. The value of the Company's investment into the LF Gresham House UK Micro Cap Fund ("Micro Cap") increased by 7.4 per cent., the LF Gresham House UK Smaller Companies Fund ("Small Cap") increased by 4.6 per cent. and the LF Gresham House Multi Cap Income Fund increased by 6.8 per cent. in the period. This was primarily due to positive news flow across the portfolio being well received by the markets with a number of trading updates demonstrating better than expected financial performance. In the Manager's regular reporting to the Board, the Directors were pleased to learn that in the six months to 31 March 2023, 85.8 per cent. of the companies in our listed portfolio have reported positive news flow in terms of the financial performance. This is very welcome news given the economic and political uncertainties we are currently experiencing.

 

Investments

I am pleased to report that the Company made two new investments totalling £1.3mn and three follow-on investments with a combined value of £3.0mn in the six months to 31 March 2023. Below are descriptions of the new investments made:

 

· Cognassist (unquoted) -a platform for supporting those with learning needs.

 

· Connect Earth (unquoted) - helps businesses track their carbon emissions.

 

· Patchworks (unquoted) - a platform for connecting businesses' applications.

 

· Oberon (quoted) - wealth advisory service for individuals and businesses.

 

· Seeen (quoted) - a video technology business.

Following the period end, a total of £1.8mn was invested as follows:

· a new unquoted investment of £0.8mn in Dayrize, a platform for assessing the sustainability of products,

 

· a followon investment of £0.6mn into Airfinity, which is in our unquoted portfolio, and

 

· a followon investment of £0.4mn into Panthera Biopartners, which is in our unquoted portfolio

Realisations

During the period both Glisser, a provider of conference and educational software and CMME, a specialist mortgage broker, went into administration. Both businesses had experienced very challenging trading conditions over the past year and their valuations had already been written down.

Following the period end, in the unquoted portfolio, Evotix was acquired resulting in a gross money multiple of 0.7x original cost. In addition, further proceeds from previous sales of unquoted investments were received as follows:

· deferred consideration from the sale of Key Travel in 2018, resulting in a gross money multiple of 3.2x original cost, and

· earnout consideration from the Pho realisation in 2021, resulted in a gross money multiple of 3.1x original cost.

In the listed portfolio, the Manager continued to take profits from partial sales of the Company's holding of Cerillion plc resulting in proceeds of £0.5mn, and a gross money multiple of 15.8x original cost.

Fundraising

I am pleased to report that during the period the Company successfully raised £25.0mn (before costs) through an offer for subscription which became fully subscribed in March 2023. The Directors are pleased to welcome the 873 new shareholders who invested for the first time and to thank the 478 existing shareholders who continue to support the Company.

The Board will consider whether to raise new funds in the 2023/24 tax year. This will be determined by the Company's cashflow and its anticipated requirements to fund new and followon investments over the next two to three years. The Board appreciates that shareholders would like plenty ofnotice of its fundraising intentions and will ensure that shareholders are informed of any such fundraising at the earliest practical time.

Consumer Duty

The Financial Conduct Authority (FCA) has introduced the concept of Consumer Duty, the rules and principles of which come into effect in July 2023. Consumer Duty is an advance on the existing concept of 'treating customers fairly' and looks to ensure good outcomes for purchasers of investment products. As a listed entity, Baronsmead Venture Trust plc, alongside other investment companies, are not themselves subject to Consumer Duty.

Instead, in their role as promoter of and Investment Manager to the Company, it is Gresham House, and any other FCA regulated parties associated with your investment in the Company, that must uphold the principles behind Consumer Duty. To that end, the Board is working with Gresham House to review the information that should be provided to assist investors and their advisers to discharge their obligations under Consumer Duty.

VCT Regulation - Financial Heath Test

 

Since the various VCT rule changes in both 2015 and 2018, VCT qualifying investments have become focussed on smaller, younger companies. As a result, when the Manager makes a new investment, they expect to make further follow-on investments as the investee company progresses and where the business case for the investment is justified. These follow-on investments are subject to the same VCT compliance rules as new deals and both rely on certain criteria being met, including the Financial Health Test.

 

The Financial Health Test is not something new and was primarily introduced as an anti-abuse regulation. However, following amendment to HMRC's guidance, there has been an effective tightening of the interpretation of the Financial Health Test. This is resulting in the restriction of potential follow-on VCT investment to support certain portfolio companies. This has the potential to negatively impact shareholders' returns as a result of portfolio companies going into administration when they might otherwise have gone on to be successful. Furthermore, as this is an industry wide issue, this measure increases the uncertainties small companies face at a particularly difficult time and may well result in unnecessary job losses and hardship to employees and their families and has the potential to reduce the overall tax efficiency of the VCT scheme as a whole.

 

The Board continues to monitor developments in this area carefully and supports the representations being made by the AIC and the VCTA to HMRC and HM Treasury to seek a change to HMRC's guidance in this area.

 

 

 

Outlook

The Board expects that market conditions will remain volatile throughout 2023 as the economic and political backdrop remain uncertain. While it is anticipated that inflation will gradually start to fall later in the year, it remains stubbornly high, and interest rates seem unlikely to fall and may rise further over the coming months.

Against this the Company's portfolio remains highly diversified, and is largely positioned in sectors which the Manager expect to provide longterm growth potential. We remain committed to investing through the economic cycle as experience suggests that this can produce superior returns over the longer term. This can also provide an opportunity for the Company to make high quality investments and build strategic stakes in businesses with great potential at good prices. This applies to both

new investments and followon investments in the portfolio. The Manager continues to see a good pipeline of potential investments and the Company remains suitably resourced to support investment into new and existing portfolio companies.

 

 

Fiona Miller Smith

Chair

12 June 2023

Investments in the period

Company

Location

Sector

Activity

Book cost

£'000

Unquoted investments

New

Cognassit UK Ltd

Newcastle upon Tyne

Healthcare & Education

A platform for supporting those with learning needs

896

Connect Earth Ltd

London 

Business Services

Helps businesses track their carbon emissions

447

Follow on

Patchworks Integration Ltd

Nottingham

Technology

A platform for connecting businesses applications

1,920

Total unquoted investments

3,263

AIM-traded Investments

New

SEEEN plc

London

Technology

A video technology business

609

Oberon Investments Group plc

London

Business Services

Wealth advisory service for individuals and businesses

471

Total AIM-traded investments

1,080

Total investments in the period

4,343

 

Realisations in the period

There were no realisations in the period.

Responsibility statement of the Directors in respect of the half-yearly financial report

Half-yearly report

The important events that have occurred during the period under review, the key factors influencing the financial statements and the principal uncertainties for the remaining six months of the financial year are set out in the Chair's statement and the Strategic report.

 

The principal risks facing the Company are mostly unchanged since the date of the Company's Annual Report for the financial year ended 30 September 2022 and continue to be as set out in that Report on pages 18 and 19.

Risks faced by the Company include but are not limited to; loss of approval as a Venture Capital Trust, legislative risk, investment performance risk, risk of economic, political and other external factors, regulatory and compliance risk and operational risk. The Board considers the aftermath of the COVID19 pandemic and the Russian invasion of Ukraine to be factors which permeate these risks, and their impacts for the remaining six months of the year continue to be kept under review.

Responsibility statement

Each Director confirms that to the best of their knowledge:

· the condensed set of financial statements has been prepared in accordance with FRS 104 Interim Financial Reporting Standards and gives a true and fair view of the assets, liabilities, financial position and profit or loss of the Company.

 

· This half-yearly report includes a fair review of the information required by:

 

a) DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of

important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and

b) DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party

transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the Company during that period; and any changes in the related party transactions described in the last annual report that could do so.

 

The half-yearly report was approved by the Board of Directors on 12 June 2023 and was signed on its behalf by Ms Fiona Miller Smith, Chair.

 

Fiona Miller Smith

Chair

12 June 2023

 

 

 

 

Condensed Income Statement

For the six months to 31 March 2023 (unaudited)

 

 

 

 

 

Six months to31 March 2023

Six months to31 March 2022

Year to 30 September 2022

 

Notes

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Losses on investments

5

-

(1,243)

(1,243)

-

23,346

23,346

-

43,626

43,626

Income

925

-

925

735

-

735

3,949

-

3,949

Investment management fee

 

(437)

(1,315)

(1,752)

(505)

(1,513)

(2,018)

(967)

(2,903)

(3,870)

Other expenses

 

(336)

-

(336)

(361)

-

(361)

(652)

-

(652)

Profit /(Loss) before taxation

 

152

(2,558)

(2,406)

(131)

(24,859)

(24,990)

2,330

(46,529)

(44,199)

Taxation on ordinary activities

 

-

-

-

-

-

-

(229)

229

-

Profit/(loss) for the period, being the total comprehensive income for the period after taxation

 

152

(2,558)

(2,406)

(131)

(24,859)

(24,990)

2,101

(46,300)

(44,199)

Return per ordinary share:

 

 

 

 

Basic and Diluted

 

2

0.05p

(0.80p)

(0.75p)

(0.05p)

(8.54p)

(8.59p)

 

0.69p

 

(15.25p)

 

(14.56p)

All items in the above statement derive from continuing operations.

 

There are no recognised gains and losses other than those disclosed in the Income Statement.

 

The revenue column of the Income Statement includes all income and expenses. The capital column accounts for the realised and unrealised profit or loss on investments and the proportion of the management fee charged to capital.

 

The total column of this statement is the unaudited Statement of Total Comprehensive Income of the Company prepared in accordance with the Financial Reporting Standard ("FRS"). The supplementary revenue return and capital return columns are prepared in accordance with the Statement of Recommended Practice issued by the Association of Investment Companies ("AIC SORP").

 

 

 

 

 

Condensed statement of changes in equity

 

For the six months to 31 March 2023 (Unaudited)

 

 

Non-distributable reserves

Distributable reserves

Total

£'000

Called-up share capital

£'000

Share

premium 

 £'000

Revaluation

reserve

£'000

Capital

reserve £'000

Revenue

reserve

£'000

At 1 October 2022

34,205

108,435

16,912

31,786

2,487

193,825

(Loss)/profit on ordinary activities after taxation

-

-

(2,307)

(251)

152

(2,406)

Net proceeds of share issues, share buybacks & sale of shares from treasury

 

 

3,674

18,970

-

(1, 516)

-

21,128

Dividends paid

 

-

-

-

(8,458)

(663)

(9,121)

At 31 March 2023

 

37,879

127,405

14,605

21,561

1,976

203,426

 

For the six months to 31 March 2022 (Unaudited)

Non-distributable reserves

Distributable reserves

Total

£'000

Called-up share capital

£'000

Share

Premium

 £'000

Revaluation

reserve

£'000

Capital

reserve £'000

Revenue

reserve

£'000

At 1 October 2021

29,501

76,711

68,763

46,248

1,640

222,863

(Loss)/ profit after taxation

-

-

(28,972)

4,113

(131)

(24,990)

Net proceeds of share issues, share buybacks & sale of shares from treasury

4,704

31,724

-

(850)

-

35,578

Dividends paid

-

-

-

(10,435)

(307)

(10,742)

At 31 March 2022

34,205

108,435

39,791

39,076

1,202

222,709

 

For the year ended 30 September 2022 (Audited)

 

Non-distributable reserves

Distributable reserves

Total

£'000

Called-up share capital

£'000

Share

premium 

£'000

Revaluation

reserve

£'000

Capital

reserve £'000

Revenue

reserve

£'000

At 1 October 2021

29,501

76,711

68,763

46,248

1,640

222,863

(Loss)/ profit after taxation

-

-

(51,851)

5,551

2,101

(44,199)

Net proceeds of share issues, share buybacks & sale of shares from treasury

4,704

31,724

-

(1,050)

-

35,378

Dividends paid

-

-

-

(18,963)

(1,254)

(20,217)

At 30 September 2022

34,205

108,435

16,912

31,786

2,487

193,825

 

Condensed Balance Sheet

As at 31 March 2023 (Unaudited)

 

 

Notes

 

As at

31 March

2023

£'000

As at31 March 2022

£'000

As at30 September 2022

£'000

Fixed assets

 

Unquoted investments

5

44,426

48,012

48,184

Traded on AIM

5

59,156

64,041

56,819

Collective investment vehicles

5

75,140

67,459

54,740

Listed on LSE

5

-

24

24

 

Investments

5

178,722

179,536

159,767

 

Current assets

 

Debtors

1,213

80

131

Cash at bank and on deposit

24,600

44,304

35,051

 

 

25,813

44,384

35,182

Creditors (amounts falling due within one year)

(1,109)

(1,211)

(1,124)

 

Net current assets

24,704

43,173

34,058

 

Net assets

203,426

222,709

193,825

 

Capital and reserves

 

Called-up share capital

37,879

34,205

34,205

Share premium

127,405

108,435

108,435

Capital reserve

21,561

39,076

31,786

Revaluation reserve

5

14,605

39,791

16,912

Revenue reserve

1,976

1,202

2,487

 

Equity shareholders' funds

203,426

222,709

193,825

 

 

Net asset value per share

57.96p

70.37p

61.29p

Number of ordinary shares in circulation

350,947,945

316,473,613

316,218,166

Condensed Statement of Cash Flows

For the six months to 31 March 2023 (unaudited)

 

Sixmonths to31 March 2023

£'000

Sixmonths to31 March2022

£'000

Year

to30 September 2022

£'000

Net cash outflow from operating activities

(1,384)

(3,765)

(2,981)

Net cash (outflow)/inflow from investing activities

(21,072)

6,076

5,713

Net cash (outflow)/inflow before financing activities

(22,456)

2,311

2,732

Net cash inflow from financing activities

12,005

24,540

14,866

 

(Decrease)/increase in cash

(10,451)

26,851

17,598

 

Reconciliation of new cash flow to movement in net cash

 

(Decrease)/increase in cash

(10,451)

26,851

17,598

Opening cash at bank and on deposit

35,051

17,453

17,453

 

Closing cash at bank and on deposit

24,600

44,304

35,051

 

Reconciliation of loss on ordinary activities before taxation to net cash outflow from operating activities

 

Loss on ordinary activities before taxation

(2,406)

(24,990)

(44,199)

Losses on investments

1,243

23,346

43,626

Changes in working capital and other non-cash items

(221)

(2,121)

(2,408)

 

Net cash outflow from operating activities

(1,384)

(3,765)

(2,981)

 

Notes to the financial statements

 

For the six months to 31 March 2023 (Unaudited)

 

1 Basis of preparation

 

The condensed financial statements for the six months to 31 March 2023 comprise the unaudited statements set out on pages 13 to 16 together with the related notes on pages 17 to 21. The Company applies FRS 102 and the AIC SORP for its annual financial statements. The condensed financial statements for the six months to 31 March 2023 have therefore been prepared in accordance with FRS 104 'Interim Financial Reporting' and the principles of the AIC SORP. They have been prepared on a going concern basis. The accounts have been prepared on the same basis as the accounting policies set out in the Company's Annual Report and Financial Statements for the year ended 30 September 2022.

 

The financial information contained in this half-yearly financial report does not constitute statutory accounts as defined in sections 434 - 436 of the Companies Act 2006. The half-yearly financial report for the six months ended 31 March 2023 and for the six months ended 31 March 2022 have been neither audited nor reviewed by the Company's auditors. The information for the year to 30 September 2022 has been extracted from the latest published audited financial statements, which have been filed with the Registrar of Companies. The report of the auditor for the audited financial statements for the year to 30 September 2022 has been extracted from the latest published audited financial statements, which have been filed with the Registrars of Companies. The report of the auditor for the audited financial statements for the year to 30 September 2022 was: (i) unqualified; (ii) did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying their report; and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006. No statutory accounts in respect of any period after 30 September 2022 have been reported on by the Company's auditors or delivered to the Registrar of Companies.

 

Copies of the half-yearly financial report have been made available to shareholders and are available from Gresham House, 80 Cheapside, London, EC2V 6EE.

 

2 Performance and shareholder returns

 

Return per share is based on a weighted average of 321,742,586 ordinary shares in issue (31 March 2022 - 290,940,471 ordinary shares; 30 September 2022 - 303,530,368 ordinary shares).

 

Earnings for the first six months to 31 March 2023 should not be taken as a guide to the results of the full financial year to 30 September 2023.

 

3. Called-up share capital

 

Allotted, called-up and fully paid:

 

Ordinary shares

£'000

342,045,641 ordinary shares of 10p each listed at 30 September 2022

34,205

36,739,031 ordinary shares of 10p each issued during the period

3,674

378,784,672 ordinary shares of 10p each listed at 31 March 2023

37,879

25,827,475 ordinary shares of 10p each held in treasury at 30 September 2022

(2,583)

2,742,252 ordinary shares of 10p each repurchased during the period and held in treasury

(274)

733,000 ordinary shares of 10p each sold from treasury during the period

73

27,836,727 ordinary shares of 10p each held in treasury at 31 March 2023

(2,784)

350,947,945 ordinary shares of 10p each in circulation* at 31 March 2023

35,095

* Carrying one vote each.

 

During the six months to 31 March 2023, the Company issued 36,739,031 shares at net proceeds of 22,334,000 (after costs). During the same period, the Company purchased 2,742,252 shares to be held in treasury at a cost of £1,622,000. The Company also sold 733,000 treasury shares at a cost of £416,000. At 31 March 2023 the Company held 27,836,727 ordinary shares in treasury. Shares may be sold out of treasury below Net Asset Value as long as the discount at issue is narrower than the average discount at which the shares were bought into treasury.

Excluding treasury shares, there were 350,947,945 ordinary shares in issue at 31 March 2023 (31 March 2022 - 316,473,613 ordinary shares; 30 September 2022 - 316,218,166 ordinary shares).

 

4. Dividends

The final dividend for the year ended 30 September 2022 of 2.75p per share (2.55p capital, 0.2p revenue) was paid on 3 March 2023 to shareholders on the register on 3 February 2023. The exdividend date was 2 February 2023.

 

During the year to 30 September 2022, the Company paid an interim dividend on 9 September 2022 of 3.0p per share (2.7p capital, 0.3p revenue).

 

5. Investments

 

All investments are initially recognised and subsequently measured at fair value. Changes in fair value are recognised in the Income Statement.

 

The methods of fair value measurement are classified into a hierarchy based on reliability of the information used to determine the valuation.

 

· Level 1 - Fair value is measured based on quoted prices in an active market.

· Level 2 - Fair value is measured based on directly observable current market prices or indirectly being derived from market prices.

· Level 3 - Fair value is measured using a valuation technique that is not based on data from an observable market.

 

The valuation of unquoted investments contained within level 3 of the Fair Value hierarchy involves key assumptions dependent upon the valuation methodology used. The primary methodologies applied are:

 

· Cost of recent investment

· Earnings Multiple

· Offer Less 10 per cent

 

The earnings multiple approach involves more subjective inputs than the cost of recent investment and offer approaches and therefore presents a greater risk of over or under estimation. Key assumptions for the earnings multiple approach are the selection of comparable companies and the use of either historic or forecast revenue or earnings, as considered most appropriate. Other assumptions include the appropriateness of the discount magnitude applied for reduced liquidity and other qualitative factors. These assumptions are described in more detail in note 2.3 in the Company's Report and Financial Statements for the year to 30 September 2022.The techniques used in the valuation of unquoted investments have not changed materially since the date of that Report.

 

 

Level 1

Level 2

Level 3

 

Traded

on AIM

£'000

 

Traded

on LSE

£'000

Collective

investment

vehicles

£'000

 

 

Unquoted

£'000

Total

£'000

Opening book cost

48,212

2,315

42,931

49,397

142,855

Opening unrealised appreciation/(depreciation)

8,607

(2,291)

11,809

(1,213)

16,912

Opening fair value

56,819

24

54,740

48,184

159,767

Movements in the period:

Purchases at cost

1,080

-

38,669

3,263

43,012

Sale - proceeds

-

(21,750)

(1,064)

(22,814)

- realised gains on sales

-

-

1,064

1,064

Change in unrealised appreciation/ (depreciation)

1,257

(24)

3,481

(7,021)

(2,307)

Closing fair value

59,156

-

75,140

44,426

178,722

Closing book cost

49,292

2,315

59,850

52,660

164,117

Closing unrealised appreciation/(depreciation)

9,864

(2,315)

15,290

(8,234)

14,605

Closing fair value

59,156

-

75,140

44,426

178,722

Equity shares

59,156

-

-

16,756

75,912

Preference Shares

-

-

-

17,508

17,508

Loan notes

-

-

-

10,162

10,162

Collective investment vehicles

-

-

75,140

-

75,140

Closing fair value

59,156

-

75,140

44,426

178,722

 

6. Other required disclosures

 

6.1 Segmental reporting

 

The Company has one reportable segment being investing in primarily a portfolio of UK growth businesses, whether unquoted or traded on AIM.

 

6.2 Principal risks and uncertainties

 

The Company's financial instruments consist of equity and fixed interest investments, cash balances and liquid resources. Its principal risks are therefore market risk, price risk, credit risk and liquidity risk. Other risks faced by the Company include loss of approval as a Venture Capital Trust, legislative, investment performance, economic, political and other external factors, regulatory and compliance and operational risks. These risks, and the way in which they are managed, are described in more detail in the principal risks and uncertainties table within the Strategic report section in the Company's Report and Financial Statements for the year to 30 September 2022. The Board continues to regularly review the risk environment in which the Company operates.

 

6.3 Related parties

 

Gresham House Asset Management Ltd (the "Manager") manages the investments of the Company. The Manager also provides or procures the provision of secretarial, administrative and custodian services to the Company. Under the management agreement, the Manager receives a fee of 2.0 per cent. per annum of the net assets of the Company. This is described in more detail under the heading 'The management agreement' within the Strategic Report in the Company's Annual Report and Financial Statements for the year to 30 September 2022. During the period the Company has incurred management fees of £1,753,000 (31 March 2022 - £2,018,000; 30 September 2022 - £3,870,000) and secretarial fees of £74,000 (31 March 2022 - £69,000; 30 September 2022 - £136,000) payable to the Manager. A performance fee of £nil has been accrued at 31 March 2023 (31 March 2022 - £nil; 30 September 2022 - £nil). This is described in more detail under the heading 'Performance fees' within the Strategic Report in the Company's Annual Report and Financial Statements for the year to 30 September 2022.

 

6.4 Going Concern

 

After making enquiries, and bearing in mind the nature of the Company's business and assets, the Directors consider that the Company has adequate resources to continue in operational existence for the foreseeable future. In arriving at this conclusion, the Directors have considered the Company's cash balances, the liquidity of the Company's investments and the absence of any gearing. The Directors are therefore also satisfied that the Company has adequate financial resources to continue in operation for at least the next 12 months and that, accordingly, it is appropriate to adopt the going concern basis in preparing the financial statements.

 

 

 

 

 

6.5 Post balance sheet events

The following events occurred between the balance sheet date and the signing of these financial statements:

 

· The 30 April 2023 NAV of 59.0p was announced on 5 May 2023 and the 31 May 2023 NAV of 59.1p was announced on 6 June 2023. At the date of publishing this report, the Board is unaware of any matter that will have caused the NAV per share to have changed significantly since the latest NAV.

 

· 3 million shares were issued on 3 April 2023 at allotment prices between 58.9p and 61.8p under the current offer.

 

· Purchased 0.7 million Ordinary Shares of 10.0p on 5 April 2023 at a price of 54.3p per share to be held in Treasury.

 

· Followon investment into Airfnity Ltd completed in April 2023 totalling £0.6mn.

 

· Followon investment into Panthera Biopartners completed in June 2023 totalling £0.4mn.

 

· Two followon investments, into Multi Cap, completed in April and May 2023, totalling £2.5mn.

 

· Two followon investments, into Small Cap, completed in April and May 2023, totalling £2.5mn.

 

· One new investment, into Dayrize B.V., completed in May 2023 totalling £0.8mn.

 

· Partial realisation in MXC Capital Ltd was made in April, following a corporate action, realising proceeds of £0.01mn and making a return of 0.6x cost.

 

· Partial realisations in Cerillion plc were made in April and May, realising proceeds of £0.5mn and making a return of 15.8x cost.

 

· Received deferred proceeds of £1.1mn from Pho in May 2023, which was realised in July 2021, making a total return of 3.1x cost.

 

· Realised Evotix in May 2023, receiving proceeds of £0.7mn, making a return of 0.7x cost.

 

· Received deferred proceeds of £0.3mn from Key Travel in May 2023, which was realised in May 2018, making a total return of 3.2x cost.

 

 

 

 

 

 

Directors

Fiona Miller Smith (Chair)

Les Gabb*

Susannah Nicklin Δ†

Michael Probin††

 

Secretary

Gresham House Asset Management Ltd

 

Registered Office

5 New Street Square

London EC4A 3TW

 

Investment Manager

Gresham House Asset Management Ltd

5 New Street Square

London EC4 3TW

Tel: 020 7382 0999

 

Registered Number

03504214

 

Registrars and Transfer Office

Computershare Investor Services PLC

The Pavilions

Bridgwater Road

Bristol BS99 6ZZ

Tel: 0800 923 1533

 

Brokers

Panmure Gordon & Co

One New Change

London EC4M 9AF

Tel: 020 7886 2500

 

Auditor

BDO LLP

55 Baker Street

London W1U 7EU

 

Solicitors

Dickson Minto W.S

Broadgate Tower

20 Primrose Street

London EC2A 2EW

 

VCT Status Adviser

PricewaterhouseCoopers LLP

1 Embankment Place

London WC2N 6RH

 

Website

www.baronsmeadvcts.co.uk

 

 Corporate Information

Δ Senior Independent Director

* Chair of the Audit Committee

† Chair of the Nomination Committee

†† Chair of the Management Engagement and Remuneration Committee

LEI: 213800VQ1PQHOJXDDQ88

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR BLGDLSUBDGXD
Date   Source Headline
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20243:17 pmRNSTotal Voting Rights
28th Mar 202411:00 amRNSShare Allotment,Total Voting Rights,Close of Offer
19th Mar 20245:37 pmRNSClose of Offer to New Applications
18th Mar 20244:46 pmRNSDirector/PDMR Shareholding
15th Mar 20244:04 pmRNSTransaction in Own Shares
6th Mar 20243:00 pmRNSNet Asset Value(s)
6th Mar 20241:22 pmRNSResult of AGM
1st Mar 202410:20 amRNSTotal Voting Rights
15th Feb 20242:05 pmRNSDirector/PDMR Shareholding
15th Feb 20242:00 pmRNSAllotment of Shares and Total Voting Rights
7th Feb 202410:00 amRNSNet Asset Value(s)
2nd Feb 20248:00 amRNSIntention to Utilise Over-allotment Facility
1st Feb 20245:18 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
30th Jan 202412:01 pmRNSDirector/PDMR Shareholding
30th Jan 202412:00 pmRNSDirector/PDMR Shareholding
26th Jan 20242:30 pmRNSAllotment of Shares and Total Voting Rights
24th Jan 20245:00 pmRNSNet Asset Value(s)
24th Jan 20244:00 pmRNSNet Asset Value(s)
22nd Jan 20243:00 pmRNSOffer Update Extension of Early Bird Discount Date
19th Jan 20242:35 pmRNSIssue of Supplementary Prospectus
5th Jan 202411:36 amRNSChange of allotment date - correction
4th Jan 20243:45 pmRNSChange of allotment date
2nd Jan 202411:00 amRNSTotal Voting Rights
22nd Dec 20237:00 amRNSAnnual Financial Report
12th Dec 20235:40 pmRNSTransaction in Own Shares
6th Dec 20231:30 pmRNSNet Asset Value(s)
24th Nov 20231:27 pmRNSPublication of a Prospectus/Offer for Subscription
22nd Nov 20237:00 amRNSCompliance with Market Abuse Regulation ("MAR")
14th Nov 202310:01 amRNSUpdate on Offer for Subscription
6th Nov 20234:01 pmRNSNet Asset Value(s)
27th Oct 20231:30 pmRNSNet Asset Value(s)
19th Oct 20234:51 pmRNSDirectorate Change
12th Oct 202311:22 amRNSAppointment of Non-Executive Director
2nd Oct 20234:00 pmRNSTotal Voting Rights
28th Sep 20235:52 pmRNSTransaction in Own Shares
12th Sep 20236:28 pmRNSTransaction in Own Shares - Replacement
12th Sep 20235:20 pmRNSTransaction in Own Shares
5th Sep 202311:00 amRNSIntention to Fundraise
4th Aug 20234:00 pmRNSNet Asset Value(s)
1st Aug 20231:52 pmRNSTotal Voting Rights
27th Jul 20234:11 pmRNSTransaction in Own Shares
24th Jul 20232:00 pmRNSNet Asset Value(s)
3rd Jul 202311:26 amRNSTotal Voting Rights
20th Jun 20233:45 pmRNSTransaction in Own Shares
13th Jun 20237:00 amRNSHalf-yearly Report
6th Jun 20235:30 pmRNSNet Asset Value(s)
12th May 20237:00 amRNSCompliance with the Market Abuse Regulation
5th May 20235:30 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.